Bacterial fatty acid synthesis (FAS) is an attractive antibacterial target, as FAS is organized differently in bacteria and mammals. 1, 2 Fatty acid biosynthesis in bacteria is crucial for the production of a number of lipid-containing components, including the cell membrane. The bacterial fatty acid system (FAS II) uses discrete monofunctional enzymes, which operate in conjunction with acyl carrier protein (ACP)-associated substrates, whereas mammalian fatty acid synthase (FAS I) is mediated by a single multifunctional enzyme-ACP complex. The differences in prokaryote and eukaryote fatty acid biosynthesis provide an attractive opportunity for selective FAS II inhibition, which is a potential strategy for the development of antibacterial agents. Bacterial enoyl-ACP reductase, which catalyzes the final and ratelimiting step in type II FAS, has been validated as a novel target for the development of antibacterial drugs. 3, 4 Three isoforms, FabI, FabK and FabL, have been detected in enoyl-ACP reductase. Most of bacteria including Staphylococcus aureus contain FabI, but Streptococcus pneumonia has FabK. Enterococcus faecalis and Pseudomonas aeruginosa were known to contain both FabI and FabK, whereas Bacillus subtilis contains both FabI and FabL. InhA is the FabI homolog from Mycobacterium tuberculosis. Indeed, the antibacterial target of triclosan 5 and isoniazid, 6 which are currently used antibacterial agents, have been determined to be the FabI and InhA, respectively. Therefore, the enoyl-ACP reductase inhibitors may prove to be interesting lead compounds for the development of effective antibacterial drugs.
In the course of our screening for inhibitors of bacterial enoyl-ACP reductase from microbial metabolites, we previously isolated aquastatin A (2) from a fungal strain Sporothrix sp. AT 28. 7 Aquastatin B (3) was obtained by acid hydrolysis from aquastatin A. Further HPLC studies on minor and less polar metabolites with a similar UV spectra have resulted in isolation of a new derivative of aquastatin A, aquastatin C (1; Figure 1 ). In this paper, we report the isolation and structure determination of 1, and the structure-activity relationship.
ISOLATION
The ethylacetate extracts from the culture broth (6 l) of Sporothrix sp. AT 28 was subjected to silica gel (56Â200 mm, Merck art no. 7734.9025, Merck, Darmstadt, Germany) column chromatography followed by stepwise elution with CHCl 3 -MeOH (10:1, 5:1, 2:1, 1:1). The active fractions eluted with CHCl 3 -MeOH (2:1) were pooled and concentrated in vacuo. The HPLC analysis of the residue dissolved in MeOH showed the presence of another peak with a similar UV spectra with that of 2. 
STRUCTURE ELUCIDATION
The molecular formula of 1 was determined to be C 29 H 48 O 9 on the basis of high-resolution ESI-MS ((M+Na) + at m/z 563.3192 (+0.1 mmu error), (MÀH) À at 539 m/z) in combination with 1 Hand 13 C-NMR data. The IR data suggested the presence of a carbonyl (1646 cm À1 ) and a hydroxyl (3428 cm À1 ) moiety ( Table 1) .
The 1 H-NMR data (Table 2 ) with the COSY spectrum suggested the presence of two aromatic protons attributable to an 1, 2, 4, 6-tetrasubstituted benzene ring at In the 13 C-NMR data, a group of methylene carbons at d 30.0-d 37.1 together with the molecular formula indicated that the aliphatic chain is the pentadecyl group. These spectral data with the molecular formula indicated that four substituents in the 1, 2, 4, 6-tetrasubstituted benzene ring are a b-galactopyranoside, a pentadecyl, a carboxylic acid methyl ester and a hydroxyl. The position of the four substituents was determined by the HMBC and NOESY spectrum ( Figure 2 ). The anomeric proton of the b-galactopyranoside at d 4.89 (H-1¢¢) showed a long-range correlation with the sp 2 quaternary carbon at d 162.1 (C-4), which was in turn long-range correlated with the two meta-coupled aromatic protons at d 6.48 (H-3) and d 6.45 (H-5). In addition, H-1¢ showed NOEs with both H-3 and H-5. This data clearly indicated that the sugar was attached with C-4. The methylene protons at d 2.80 (H-9) of the pentadecyl group showed HMBC correlations with C-5 and two sp 2 quaternary carbons at d 108.1 (C-1) and d 148.2 (C-6). In addition, the long-range correlations from H-5 to C-1, C-3, C-4 and C-9 and from H-3 to C-1, C-2, C-4 and C-5 were observed. These spectral data indicated that the carboxylic acid methyl ester, the hydroxyl and the pentadecyl group were attached with C-1, C-2 and C-6, respectively. Thus, the structure of 1 was determined to be a new glycoside of 2-hydroxy-6-pentadecyl benzoic acid methyl ester as shown in Figure 1 .
Acid hydrolysis of compound 2
Compound 2 (47 mg) dissolved in 0.4 ml MeOH was treated with HCl (2.4 ml) and then stirred overnight at room temperature. The resulting hydrolysate was then extracted twice with ethyl acetate (20 ml) and the extract was concentrated in vacuo. The residue dissolved in MeOH was applied to SiO 2 TLC developed with CHCl 3 -MeOH (7:1) to yield 5 (2.8 mg) and 6 (2.9 mg) at R f of 0.80 and 0.50, respectively. Aquastatin C is a new derivative of aquastatin A, in which the 2-hydroxy-6-methyl benzoic acid ring of aquastatin A was deleted. Aquastatin C could be a direct fermentation product, not artifact that was hydrolyzed by some kind of esterase from the producing strain, because derivatives of aquastatin C with an unsaturated acyl group instead of the pentadecyl were also detected even though the exact position of the double bond was not determined. Aquastatin A and its related compounds KS-501 and KS-502 have a common structure, in which two aromatic rings are linked by an ester bond, and a sugar and a pentadecyl group are attached with the ring. [8] [9] [10] Aquastatin C is a rare metabolite incorporating one aromatic ring in its structure. Aquastatin B is a deglycosylated product derived from acid hydrolysis of aquastatin A. 8 Previously aquastatins A and B were reported to strongly inhibited bacterial enoyl-ACP reductases including S. aureus FabI and S. pneumoniae FabK in a dose-dependent manner. 7 Also aquastatins A and B were reported to exert antibacterial activity against the Gram-positive pathogens, including S. aureus, methicillin-resistant S. aureus and S. pneumonia. However, an active moiety for anti-enoyl-ACP reductases activity of aquastatins A and B has not been determined yet.
Effect of aquastatin C against enoyl-ACP reductases and bacterial growth was investigated according to the previously reported method. 11 Interestingly, aquastatin C did not inhibit S. aureus FabI and S. pneumoniae FabK even at 100 mM (Table 3) . Consistent with no inhibition against the enoyl-ACP reductases, aquastatin C did not prevent bacterial growth of S. aureus, methicillin-resistant S. aureus and S. pneumonia. To more clearly examine the structure-activity relationship, effects of 2-hydroxy-6-methyl-benzoic acid (4) and 2,4-dihydroxy-5-pentadecyl-benzoic acid methyl ester (5) against enoyl-ACP reductases and bacterial growth was investigated. Compound 5 was obtained from acid hydrolysis of 2. As 5-methyl-benzene-1,3-diol (6) was made instead of 2,4-dihydroxy-6-methyl-benzoic acid from the acid hydrolysis, 4 was purchased (Johnson Matthey Company, UK). Interestingly, all of 4-6 did not inhibited S. aureus FabI as well as S. pneumoniae FabK even at 100 mM (Table 3) . These compounds also did not show antibacterial activity against S. aureus, methicillinresistant S. aureus and S. pneumonia. These results clearly indicated that both 2-hydroxy-6-methyl-benzoic acid and 2,4-dihydroxy-5-pentadecyl-benzoic acid are important for its anti-enoyl-ACP reductase activity as well as antibacterial activity. As InhA is the FabI homolog from Mycobacterium tuberculosis, effect of aquastatins A-C, and related compounds on M. tuberculosis InhA was examined. Aquastatins A and B inhibited M. tuberculosis InhA with IC 50 of 9.6 and 18.4 mM, respectively, whereas aquastatin C and other compounds did not affect at 100 mM. Aquastatin A showed weak anti-bacterial activity against M. tuberculosis with inhibiting bacterial growth of M. tuberculosis by 17.9% at 128 mg ml À1 . The weak antibacterial activity of aquastatin A against M. tuberculosis may be because of permeability barrier, as M. tuberculosis contains a thick cell wall compared with S. aureus. In summary, aquastatin C is a rare metabolite incorporating one aromatic ring with a sugar and an aliphatic chain, which was isolated from liquid fermentation cultures of Sporothrix sp. FN611. Aquastatin C is a new glycoaromatic derivative of aquastatin A in which the 2-hydroxy-6-methyl benzoic acid ring of aquastatin A was deleted. Aquastatin C completely lost inhibitory activity of aquastatin A against bacterial enoyl-ACP reductases, such as S. aureus FabI, S. pneumoniae FabK and M. tuberculosis InhA. Also aquastatin C did not inhibited bacterial growth of S. aureus, methicillin-resistant S. aureus and S. pneumonia. The 2-hydroxy-6-methyl benzoic acid, the other moiety of aquastatin A, as well as the 2,4-dihydroxy-5-pentadecyl-benzoic acid methyl ester also did not show the FabI-inhibitory and antibacterial activity, indicating that both moieties are necessary for its inhibitory activity against enoyl-ACP reductases and bacterial growth. These results could provide new insights into the development of a selective mechanism-based antibacterial agent with targeting FabI.
